Valneva SE, a prominent player in the biotechnology sector, has been making significant strides in the health care industry with its focus on developing and commercializing vaccines aimed at combating infectious diseases. Based in Nantes, France, Valneva SE operates on a global scale, leveraging its expertise to address some of the most pressing health challenges of our time.
As of August 9, 2026, Valneva SE’s stock closed at 2.33 EUR on the NYSE Euronext Paris, reflecting a market capitalization of 433.34 million EUR. Despite a challenging financial landscape, evidenced by a price-to-earnings ratio of -2.9, the company’s strategic initiatives and innovative approaches continue to position it as a key player in the biotech industry.
Valneva SE’s product portfolio includes IXIARO/JESPECT, a vaccine designed for the prevention of Japanese encephalitis, and Dukoral, which targets cholera and diarrhea caused by enterotoxigenic Escherichia coli, primarily for travelers. These products underscore the company’s commitment to addressing global health needs, particularly in regions where these diseases are prevalent.
Beyond its existing products, Valneva SE is actively developing vaccines for a range of other infectious diseases, including Clostridium difficile, Lyme disease, chikungunya, and Zika. These efforts highlight the company’s proactive approach to emerging health threats and its dedication to expanding its vaccine offerings.
A cornerstone of Valneva SE’s strategy is its collaboration with biopharmaceutical and pharmaceutical companies, as well as academic institutions. Through these partnerships, the company leverages its proprietary EB66 vaccine production cell line and IC31 adjuvant, which are integral to its vaccine development technologies. These collaborations not only enhance Valneva SE’s research capabilities but also facilitate the advancement of its vaccine candidates.
Since its initial public offering on June 29, 2007, Valneva SE has demonstrated resilience and adaptability in a dynamic industry. The company’s ability to navigate market fluctuations is evident in its stock performance, which has seen a 52-week high of 5.415 EUR on August 17, 2025, and a low of 2.033 EUR on July 23, 2026.
Valneva SE’s commitment to innovation and global health is further reflected in its operational footprint, with activities spanning multiple countries. This international presence enables the company to address diverse health challenges and contribute to the global fight against infectious diseases.
For more information about Valneva SE and its initiatives, interested parties can visit the company’s website at www.valneva.com . As Valneva SE continues to advance its vaccine development efforts, it remains a vital contributor to the health care sector, dedicated to improving public health outcomes worldwide.
